Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

2020 American College of Rheumatology Guideline for the Management of Gout
John FitzGerald, Nicola Dalbeth, Ted R. Mikuls, et al.
Arthritis Care & Research (2020) Vol. 72, Iss. 6, pp. 744-760
Open Access | Times Cited: 654

Showing 51-75 of 654 citing articles:

Targeting Neutrophil Extracellular Traps in Gouty Arthritis: Insights into Pathogenesis and Therapeutic Potential
Cantao Li, Chenxi Wu, Fenfen Li, et al.
Journal of Inflammation Research (2024) Vol. Volume 17, pp. 1735-1763
Open Access | Times Cited: 8
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis
Jianhao Deng, Peng‐hui Lai, Li‐shan Xie, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 3
Open Access | Times Cited: 7
Burden of gout among different WHO regions, 1990–2019: estimates from the global burden of disease study
Shoheera Punjwani, Chinmay Jani, Weitao Liu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Changes in alcohol intake and serum urate changes: longitudinal analyses of annual medical examination database
Sho Fukui, Masato Okada, Tomohiro Shinozaki, et al.
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 8, pp. 1072-1081
Open Access | Times Cited: 6
The development and evaluation of dose‐prediction tools for allopurinol therapy (Easy‐Allo tools)
Daniel F. B. Wright, Hailemichael Zeru Hishe, Sophie L. Stocker, et al.
British Journal of Clinical Pharmacology (2024) Vol. 90, Iss. 5, pp. 1268-1279
Open Access | Times Cited: 6
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease ― Japanese Guideline on the Management of Asymptomatic Hyperuricemia ―
Ichiro Hisatome, Peili Li, Junichiro Miake, et al.
Circulation Journal (2020) Vol. 85, Iss. 2, pp. 130-138
Open Access | Times Cited: 42
Early onset of hyperuricemia is associated with increased cardiovascular disease and mortality risk
Lijun Li, Maoxiang Zhao, Chi Wang, et al.
Clinical Research in Cardiology (2021) Vol. 110, Iss. 7, pp. 1096-1105
Closed Access | Times Cited: 40
Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials
Lisa K. Stamp, Christopher Frampton, Melanie Birger Morillon, et al.
The Lancet Rheumatology (2021) Vol. 4, Iss. 1, pp. e53-e60
Closed Access | Times Cited: 40
Management and Cure of Gouty Arthritis
Sarah Keller, Brian F. Mandell
Medical Clinics of North America (2021) Vol. 105, Iss. 2, pp. 297-310
Closed Access | Times Cited: 39
Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia
Kazuomi Kario, Masafumi Nishizawa, Mari Kiuchi, et al.
Journal of Clinical Hypertension (2021) Vol. 23, Iss. 2, pp. 334-344
Open Access | Times Cited: 33
Pharmacogenomics in the era of next generation sequencing – from byte to bedside
Laura Russell, Yitian Zhou, Ahmed A. Almousa, et al.
Drug Metabolism Reviews (2021) Vol. 53, Iss. 2, pp. 253-278
Open Access | Times Cited: 33
Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications
Nicole Leung, Kevin Yip, Michael H. Pillinger, et al.
Mayo Clinic Proceedings (2022) Vol. 97, Iss. 7, pp. 1345-1362
Open Access | Times Cited: 27
A glance into the future of gout
Francisca Sivera, Mariano Andrés, Nicola Dalbeth
Therapeutic Advances in Musculoskeletal Disease (2022) Vol. 14
Open Access | Times Cited: 27
Environmental Triggers of Hyperuricemia and Gout
Lindsay N. Helget, Ted R. Mikuls
Rheumatic Disease Clinics of North America (2022) Vol. 48, Iss. 4, pp. 891-906
Open Access | Times Cited: 27
Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom
Mark Russell, Andrew I Rutherford, Benjamin Ellis, et al.
The Lancet Regional Health - Europe (2022) Vol. 18, pp. 100416-100416
Open Access | Times Cited: 26
Update on Uric Acid and the Kidney
Giana Kristy Ramos, David S. Goldfarb
Current Rheumatology Reports (2022) Vol. 24, Iss. 5, pp. 132-138
Closed Access | Times Cited: 25
Emerging strategies for treating gout
Edward M. Huddleston, Angelo Gaffo
Current Opinion in Pharmacology (2022) Vol. 65, pp. 102241-102241
Closed Access | Times Cited: 23
Chronic rheumatologic disorders and cardiovascular disease risk in women
Puja K. Mehta, Rebecca D. Levit, Malissa J. Wood, et al.
American Heart Journal Plus Cardiology Research and Practice (2023) Vol. 27, pp. 100267-100267
Open Access | Times Cited: 16
Management of Patients with Gout and Kidney Disease: A Review of Available Therapies and Common Missteps
Vijay Kannuthurai, Angelo Gaffo
Kidney360 (2023) Vol. 4, Iss. 9, pp. e1332-e1340
Open Access | Times Cited: 14
Models of gouty nephropathy: exploring disease mechanisms and identifying potential therapeutic targets
Lin Wang, Xiaoyu Zhang, Jiayan Shen, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 6
Traditional herbal medicine: Therapeutic potential in acute gouty arthritis
Siwei Wang, Wei Liu, Bowen Wei, et al.
Journal of Ethnopharmacology (2024) Vol. 330, pp. 118182-118182
Open Access | Times Cited: 6
Fatty acid oxidation-induced HIF-1α activation facilitates hepatic urate synthesis through upregulating NT5C2 and XDH
Ningning Liang, Xuan Yuan, Lili Zhang, et al.
Life Metabolism (2024) Vol. 3, Iss. 5
Open Access | Times Cited: 6
Nonlinearity association between hyperuricemia and all-cause mortality in patients with chronic kidney disease
Yafei Liu, Liang Han, Yin-Hong Geng, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Moving urate-lowering therapy in gout beyond guideline recommendations
Lisa K. Stamp, Nicola Dalbeth
Seminars in Arthritis and Rheumatism (2024) Vol. 65, pp. 152358-152358
Open Access | Times Cited: 5
Association between hyperuricemia and long-term mortality in patients with hypertension: results from the NHANES 2001–2018
Yufeng Yin, Erye Zhou, Jian Wu
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 5

Scroll to top